Navigation Links
IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial

sponse (CR), 2 partial responses (PR) and 6 stable disease (SD)) with duration of response ranging from 9.4 to 26.5 months. -- Assessment of pathological response in target sites in 4 patients (2 PR, 2 SD) showed: -- complete pathological regression after resection of target sites in 2 patients; and -- two patients were rendered free of disease after clinical stable disease and surgery of lung metastases. -- Progression free survival (PFS) was 4.8 months with a median follow-up of 12 months. -- Overall survival (OS) has not yet been reached as 21 patients are still alive. The survival rate at 9 months was 70%. -- Immune response: 26 out of 29 evaluated patients (90%) showed detectable TAA-specific CD8+ T cells with 18 patients (62%) showing boosted or appearance of anti-TAA specific CD8+ T cells. -- UVIDEM was well tolerated with toxicity limited to mild events with only one possibly related serious adverse event (SAE) reported (age related macular degeneration).

About UVIDEM

UVIDEM is a therapeutic specific immunostimulant developed by IDM Pharma in partnership with sanofi-aventis. Sanofi-aventis has worldwide marketing rights to UVIDEM in melanoma. UVIDEM consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines. UVIDEM is produced in IDM Pharma GMP manufacturing facilities in Irvine, California and in Paris, France. UVIDEM has been administered to 143 patients in clinical development. Completion of patient enrollment in two Phase II clinical trials was previously announced. Thirty-eight patients with malignant melanoma were included in the US Phase II study and 53 patients with resected stage II/III melanoma were included in the European randomized Phase II study.

About Melanoma

According to the American Cancer Society, in 2007 approximately 59,940
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ( ... "Dental Consumables Market - Global Industry Analysis, Size, Share, ... to their offering. (Logo: ... which are used on patients in order to treat ...
(Date:1/15/2014)... OAKS, Calif. , Jan. 15, 2014 ... Amgen (NASDAQ: AMGN ) announced today ... jointly discover and validate new therapeutic targets and ... a chronic disorder that affects millions worldwide. The ...
(Date:1/15/2014)... an unprecedented effort to curb the spread of "superbugs" such as ... an advanced and portable UV germicidal lamp manufactured by MRSA-UV is ... In order to prevent EMS paramedics and transport patients ... Palm Beach Fire Rescue is the first in the ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2
... Remission / Unconfirmed Complete Remission Rate 3.5 Fold Higher ... Compared to Standard ... and MTA: CTIC) announced today that it achieved the primary,efficacy ... for patients with advanced, relapsed aggressive non-Hodgkin,s,lymphoma (NHL) based on ...
... PRINCETON, N.J., Nov. 10 Pharmasset, Inc.,(Nasdaq: VRUS ... ITMN ) today,announced that the first patients have been ... with the hepatitis C virus (HCV).,The trial (run in ... to,investigate the combination of two oral antiviral molecules in ...
Cached Medicine Technology:Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 2Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 3Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 4Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C 2Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C 3Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C 4Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C 5
(Date:4/23/2014)... scientific director at the National Institute of Arthritis and ... 2014 recipient of the Ross Prize in Molecular Medicine, ... Molecular Medicine . The award will be given on ... in Manhattan, followed by scientific presentations by Dr. O,Shea ... National Institutes of Health. , The award, which includes ...
(Date:4/23/2014)... University researchers have identified an important enzyme pathway that ... too few chromosomes, a condition that has been directly ... associate professor of biochemistry, found that near the end ... enzyme that ensures any breaks in DNA are fully ... genome to daughter cells. This process helps safeguard against ...
(Date:4/23/2014)... that can rapidly screen a large cell population ... that population has been seriously lacking," said Virginia ... Royal Society of Chemistry journal Chemical Science ... coworkers have developed a novel technique that detects ... Sci. , 2014, DOI: 10.1039/C4SC00578C, http://pubs.rsc.org/en/content/articlelanding/2014/sc/c4sc00578c#!divAbstract ). ...
(Date:4/23/2014)... April 21, 2014 Five for-profit and non-profit ... $1.25 million in Proof of Concept grants to ... into commercial products, the Life Sciences Discovery Fund ... Entrepreneur Mentoring Program grant to the Washington Biotechnology ... advisory network to train the next generation of ...
(Date:4/23/2014)... as Ritalin, may prevent the depletion of self-control, according ... journal of the Association for Psychological Science. , Self-control ... trying to focus attention on a boring textbook are ... explanation for this difficulty: Exerting self-control for a long ... effectively on subsequent tasks. , "It is as if ...
Breaking Medicine News(10 mins):Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:ADHD drug may help preserve our self-control resources 2
... Will Retire from the Lilly ... Board, ... LLY ) has elected Michael L. Eskew, former,chairman and chief executive officer ... Eskew will stand for election,by the shareholders at the 2008 annual meeting in ...
... Feb. 19 WeissComm Partners,the largest independent ... announced the appointment of Tom Jones as ... Corporation,where he was executive director of communications, ... relations programs for the,company,s growth driver brands. ...
... Nation,s 6th Best Hospital, DENVER, Feb. ... Board: GLOB), an international e-Health, medical,information technology ... has signed an agreement with NewYork-Presbyterian,Hospital (NYP), ... in the,world, to license its SafeTrace Tx(R) ...
... under control, researchers say , , TUESDAY, Feb. 19 (HealthDay ... blood pressure under control, and this may help explain ... pressure. , That,s just one of a series of ... of the journal Hypertension . The issue commemorates ...
... While Cutting Prices for,Existing Drugs, According to a ... Mass., Feb. 19 Decision Resources, Inc., one,of ... on,pharmaceutical and healthcare issues, finds that Japan has ... for 2008 and beyond.,The changes reflect the Japanese ...
... Feb. 19 Arcapita Inc., a leading private,equity investment ... its,affiliates have agreed to sell TLC Health Care Services, ... AMED ), for an enterprise value of,$395 million., ... York, TLC is the,largest privately-held home healthcare provider in ...
Cached Medicine News:Health News:Michael L. Eskew Elected to Lilly Board of Directors 2Health News:WeissComm Partners Names Tom Jones Managing Director to Deepen Global Product Communications Offering 2Health News:Global Med Technologies(R), Inc. Adds Internationally Renowned NewYork- Presbyterian Hospital to Client List 2Health News:Global Med Technologies(R), Inc. Adds Internationally Renowned NewYork- Presbyterian Hospital to Client List 3Health News:Global Med Technologies(R), Inc. Adds Internationally Renowned NewYork- Presbyterian Hospital to Client List 4Health News:Hypertension a Health Challenge for Women 2Health News:Hypertension a Health Challenge for Women 3Health News:Japan Backs Away from Making Real Changes to Its Rx Pharma Pricing Mechanism 2Health News:Arcapita to Sell TLC Health Care Services, Inc. for $395 Million 2
... Gore's EXCLUDER AAA Endoprosthesis is an ... invasive treatment option for patients with abdominal ... a durable ePTFE bifurcated graft with an ... both device flexibility and material durability. The ...
... remove a cast from an arm or leg ... are cut or burned by the cast saw ... to remove any cast with confidence. This innovative, ... and burns from the cast saw and can ...
... choice plays an important part in ... particularly where reduced capsule formation, inflammation ... considerations. GORE-TEX Suture, a nonabsorbable, ePTFE ... characteristics sought by a variety of ...
... Patch utilizes advanced fluoropolymer technology, ... penetrating suture and decrease suture ... as 88 percent. This improvement, ... multi-directional strength and low thrombogenicity, ...
Medicine Products: